ASH 2017

ASH 2017

Fred Hutch scientists are presenting new research findings at the American Society of Hematology (ASH) Annual Meeting, the world's most comprehensive hematology event, on December 9-12, 2017. 

The meeting features the E. Donnall Thomas Lecture and Prize, created in 1992 and named after the late Nobel laureate and past society president. The lecture and prize recognizes pioneering research achievements in hematology that have represented a paradigm shift or significant discovery in the field.

The ASH Mentor Award will be posthumously given to Dr. Oliver Press, who died earlier in 2017, to recognize his excellence in mentoring colleagues and trainees.

Fred Hutch researchers are presenting nearly 50 talks and posters on a number of topics including immunotherapy, gene therapy, hematopoietic transplantation, and quality of life and survivorship.

805 Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy

Cameron Turtle, MBBS, PhD
Monday, December 11, 2017, 4: 30 PM
Bldg. C, Lvl 1, Hall C4 (Georgia World Congress Center)

CD19 chimeric antigen receptor (CAR)-modified T cell therapy has produced impressive results in patients (pts) with CD19+B cell malignancies; however, treatment can be complicated by neurologic adverse events (AEs). The presentation and pathogenesis of neurotoxicity (NT) are incompletely understood. Read more >

SCI-14 Understanding Outcomes of CD19-Targeted CAR T Cell Immunotherapy

Cameron Turtle, MBBS, PhD
Saturday, December 9, 2017, 9:30 AM-11:00 AM
Bldg C, Lvl 1, Hall C4 (Georgia World Congress Center)

Saturday, December 9, 2017, 2:00 PM-3:30 PM
Bldg C, Lvl 1, Hall C1 (Georgia World Congress Center)

CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in patients with relapsed and/or refractory B cell malignancies, but factors that impact toxicity and efficacy have been difficult to define because of heterogeneity of CAR-T cells administered to individual patients. We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 ratio of CD4+:CD8 +CAR-T cells to adults with CD19+ acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) after lymphodepletion chemotherapy. Read more >

73 Comparison of Chronic Graft-Versus-Host Disease Severity and Functional Status after Cord Blood, Haploidentical Related and 1-Allele Mismatched Unrelated Donor Hematopoietic Cell Transplantation

Stephanie Lee, MD (senior author)
Presenter: Kareem Jamani, MD
Saturday, December 9, 2017, 4:45 PM
Bldg B, Lvl 3, B302-B303 (Georgia World Congress Center)

Autologous (auto) and allogeneic (allo) hematopoietic cell transplant (HCT) recipients face a prolonged post-HCT recovery. Given the extent of supportive care needed post-HCT, recipients are required to have an informal caregiver (IC). ICs are typically spouses, siblings, children or parents of recipients. ICs are critical to post-HCT care, providing emotional support, medication management, assistance with activities of daily living and other vital care that spans months to years of recipient recovery. Given the commitment and responsibility that caregiving requires, it follows that ICs may be burdened. To date, small studies have found that HCT ICs may experience significant levels of distress and burden, as well as poor quality of life (QoL) after HCT. Here we report a large cross-sectional evaluation of HCT IC QoL. Read more >

1552 Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

David Maloney, MD, PhD
Saturday, December 9, 2017, 5:30 PM - 7:30 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

JCAR017 is a CD19-directed 4-1BB CAR T cell product administered in a defined composition at a precise dose of CD8 and CD4 CAR T cells. TRANSCEND NHL 001 is the first multicenter Ph1 trial of JCAR017 in relapsed/refractory (R/R) B-cell NHL (NCT02631044; interim results previously reported (Abramson, 14-ICML 2017)) that will enroll a planned pivotal cohort later this year. Preliminary safety data show lower rates of all grade cytokine release syndrome (CRS) and neurotoxicity (NT) than reported for other CD19-directed CAR T cell products with broad heterogeneity of CAR T cell dosing and cell composition characteristics, though all grade events for all of those products have not been reported. Based on these data, we have begun to administer JCAR017 in the outpatient setting and plan to have a proportion of patients in the pivotal cohort treated as outpatients. Herein we update the safety and tolerability of JCAR017 and adverse event (AE) management in R/R B-NHL patients on the ongoing TRANSCEND NHL 001 trial (NCT02631044).  Read more >

Stories from ASH


Hutch Team

For more information or to arrange an interview, please contact Jonathan Rabinovitz at 206.658.7612 or email our media relations team.